ASH 2020 | Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, discusses the three-year follow-up of a Phase II study (NCT02427451) aiming to evaluate the efficacy and safety of fixed duration combined obinutuzumab, ibrutinib and venetoclax treatment in chronic lymphocytic leukemia (CLL). The study continues to show impressive results, with a 95% 36-month estimated progression-free survival (PFS) rate for both relapsed/refractory and treatment-naïve patients. High overall response rates and measurable residual disease negativity rates were also shown. No long-term toxicities have been identified thus far. Longer follow-up is needed to evaluate the durability of remissions. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
